PapersPMID:39042390
Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.
- 01 · finding
- 1
- 02 · compound
- 1
- 03 · endpoint
- 1
- 04 · null
- 0
What it reported
How to read these marksWhat moved
1 finding
berberine — decreases alanine aminotransferase
Evidence strength: very limited.Findingreplicated ×1“After a 12-week intervention, the BBR group demonstrated a statistically significant decrease in alanine transaminase (ALT) p=0.0105, and de Ritis ratio p=0.0011 compared to the control group.”
Quoted verbatim from Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- berberine 1500 mg/day, oral, 12 weeks
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD)
Does berberine impact anthropometric, hepatic, and metabolic parameters in patients with metabolic dysfunction-associated fatty liver disease? Randomized, double-blind placebo-controlled trial.2024PMID:3904239010.26402/jpp.2024.3.06Permalink
Study record
Read under: berberine
- Design
- randomised controlled trial
- Species
- human
- Population
- adults with metabolic dysfunction-associated fatty liver disease (MAFLD)
- Participants
- not recorded
- Comparator
- not stated in the paper
- Duration
- 84 days
- Endpoints
- 4
- Record
- extracted
- Readings recorded
- 2